Verition Fund Management
ALDX icon

Verition Fund Management’s Aldeyra Therapeutics ALDX Stock Holding History

Verition Fund Management’s Portfolio ALDX Stock Details ALDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-529,200
Closed -$4.44M – 2316
2023
Q2 		$4.44M Buy
+529,200
New +$5.21M 0.06% 401
2021
Q4 		– Sell
-300,000
Closed -$2.63M – 2516
2021
Q3 		$2.63M Buy
+300,000
New +$2.75M 0.02% 487

Other funds holding ALDX

KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AAP
Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Verition Fund Management's ALDX Position: Q2 2025 in Review

Verition Fund Management sold out of Aldeyra Therapeutics (ALDX) in Q2 2025, closing a stake of 37,505 shares — an estimated $216K sold.

Verition Fund Management first reported a position in ALDX in Q4 2018 and held it in 21 quarters. The position peaked at $15.5M in Q1 2023. 121 funds tracked by Wall St. Rank hold ALDX as of Q2 2025.

  • Verition Fund Management reported no remaining Aldeyra Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Verition Fund Management sold 37,505 Aldeyra Therapeutics shares in Q2 2025, an estimated $216K.
  • Verition Fund Management first reported a position in Aldeyra Therapeutics in Q4 2018 and held it in 21 quarters.
  • Verition Fund Management's Aldeyra Therapeutics position peaked at $15.5M in Q1 2023.
  • 121 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q2 2025.

Based on Verition Fund Management's 13F filing for Q2 2025, filed 14 Aug 2025.